|  |
| --- |
| Project Information  |
| **Project Name** | Sample Project Title | **Date**  | 01/01/2018  |
| **RITM** |       |
| **CS** |       |
| **Requestor Name** | Your Name | **Email** | your.email@ucsf.edu |
| **Primary Investigator** | Study PI Name | **Email** | pi.name@ucsf.edu |
| **IRB Number** | 01-23456  | **IRB Expiration Date** | 01/01/2019 |
| **IRB PI Name** | PI Name | **IRB PI Email** | pi.email@ucsf.edu |
| **Will you need Data Management Services?**  |  |
| **Will this Report/Data Set be Shared with a Non-UCSF Third Party?** |  |
| **Third Party Contact Information** | **Will the third party take possession of the data set/report on their third-party system?** |   |
| Name: Other InvestigatorInstitution: UCSD Email: other.pi@ucsd.eduPhone: 012-345-6789 | **Name of third-party System:**  | UCSD MyResearch  |
| **Is this third-party system in its final design?**  |   |
| Funding Information  |
| **Business Unit** | **Fund** | **Department ID** | **Project ID** | **Function**  |  **Activity Period** |
|  | 0000 | 012345 | 0123456 | 01 | 01 |
| Data Pull Frequency | **Patient contact for recruitment?** | **MyResearch Account Name** | **UCSF/ZSFGH** | **De-identified, Identified, or Limited Dataset**[[1]](#footnote-1) |
|   |  | username\_shared | [x]  UCSF[ ]  ZSFGH |  |

|  |
| --- |
| Data Request Information |
| General Description | We are seeking help with identify potential subjects from ZSFGH for a retrospective study on the effects of antivirals to treat HCV. |
| Datasets | UCSF |
| Cohort | UCSF patients with at least one outpatient encounter at ZSFGH since January 1, 2014 who were age 18 years or older at the time of an outpatient encounter And: HIV/HCV coinfected patients at UCSF who were treated for HCV using a sofosbuvir based direct acting antiviral (DAA) to treat their hepatitis C (HCV). |
| Inclusion Criteria | One or more HIV diagnosis codes:

|  |  |
| --- | --- |
| current\_icd10\_list | current\_icd9\_list |
| B20 | 042 |
| Z21 | V08 |

And: Prescribed Sofosbuvir based DAA Medication with a Generic Name or LEDIPASVIR or SOFOSBUVIR

|  |  |  |
| --- | --- | --- |
| GENERIC\_NAME | NAME | medication\_id |
| ledipasvir-sofosbuvir oral | HARVONI ORAL | 219720 |
| sofosbuvir 400 mg tablet | SOFOSBUVIR 400 MG TABLET | 215826 |

 |
| Expected Cohort | ~1000 |
| Exclusion Criteria | < 18 years of age |
| Data Elements | * MRN
* Date of Birth
* Date of death, if applicable
* Date of first DX of HIV+
* Medication name/start/stop dates for above listed sofosbuvir based DAA medications starting from the date of the first DX of HIV+ to December 31, 2017.
* All LAB results and dates for the below labs starting from the date of the first DX of HIV+ to December 31, 2017.

|  |  |  |
| --- | --- | --- |
| Name | component\_id | loinc\_code |
| HCV AB (EXTERNAL LAB) | 1810775 | 48159-8 |
| HCV ANTIBODY | 9370 | 16128-1 |
| HCV ANTIBODY (EXTERNAL LAB) | 3446 | 48159-8 |
| HCV ANTIBODY (BSI) | 1703 | 47365-2 |
| HCV ANTIBODY (EXTERNAL LAB) | 3447 | 13955-0 |

 |
| UCSF Required Acknowledgement |
| All publications resulting from the utilization of UCSF Academic Research Services and CTSI resources are required to credit the CTSI grant by including the NIH Funding Acknowledgement provided below.  In addition, please consider inviting your Academic Research Services analyst to become an author on your manuscript if his or her contributions meet the criteria for authorship.  This typically includes the acquisition of data as well as a contribution to drafting the manuscript. NIH Funding Acknowledgement:  This publication [or project] was supported by UCSF Academic Research Systems, and by the National Center for Advancing Translational Sciences, National Institutes of Health, through **UCSF-CTSI Grant Number**UL1 TR991872. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of UCSF or the NIH. |

1. [Definitions of de-identified, identified, and limited dataset](http://irb.ucsf.edu/definitions) [↑](#footnote-ref-1)